title: Genetic variations in the α(2A)-adrenoreceptor are associated with blood pressure response to the agonist dexmedetomidine.
abstract: BACKGROUND
  α(2A)-Adrenoceptors (α(2A)-ARs) have important roles in sympathetic cardiovascular regulation. Variants of ADRA2A affect gene transcription and expression and are associated with insulin release and risk for type 2 diabetes. We examined whether ADRA2A variants are also associated with cardiovascular responses to the selective α(2)-AR-agonist dexmedetomidine.
  
  
  RESULTS
  Seventy-three healthy subjects participated in a placebo-controlled, single-blind study. After 3 infusions of placebo, subjects received 3 incremental infusions of dexmedetomidine (cumulative dose, 0.4 μg/kg). Primary outcomes were changes in systolic blood pressure (SBP) and plasma norepinephrine concentrations, measured as difference of the area-under-the-curve during placebo and dexmedetomidine infusions (ΔAUC). We used multiple linear regression analysis to examine the associations between 9 ADRA2A tagging variants and 5 inferred haplotypes and ΔAUC after adjustment for covariates. Homozygous carriers of rs553668 and the corresponding haplotype 4, previously associated with increased α(2A)-AR expression, had a 2.2-fold greater decrease in AUC(SBP) after dexmedetomidine (adjusted P=0.006); similarly, the maximum decrease in SBP was 24.7±8.1 mm Hg compared with 13.6±5.9 mm Hg in carriers of the wild-type allele (P=0.007). Carriers of haplotype 3, previously associated with reduced α(2A)-AR expression, had a 44% smaller decrease in AUC(SBP) (P=0.013). Haplotype information significantly improved the model predicting the decrease in SBP (P<0.001). There were similar but nonsignificant trends for diastolic blood pressure and heart rate. Genotypes were not significantly associated with norepinephrine responses.
  
  
  CONCLUSIONS
  Common ADRA2A variants are associated with the hypotensive response to dexmedetomidine. Effects of specific variants/haplotypes in vivo are compatible with their known effects on gene expression in vitro.
authors.affiliation: Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN 37232, USA.
authors.forename: Daniel
authors.initials: D
authors.lastname: Kurnik
authors.forename: Mordechai
authors.initials: M
authors.lastname: Muszkat
authors.forename: Chun
authors.initials: C
authors.lastname: Li
authors.forename: Gbenga G
authors.initials: GG
authors.lastname: Sofowora
authors.forename: Eitan A
authors.initials: EA
authors.lastname: Friedman
authors.forename: Mika
authors.initials: M
authors.lastname: Scheinin
authors.forename: Alastair J J
authors.initials: AJ
authors.lastname: Wood
authors.forename: C Michael
authors.initials: CM
authors.lastname: Stein
mesh_terms: D058647:Adrenergic alpha-2 Receptor Agonists / Q000008:administration & dosage*; D000328:Adult; D000483:Alleles; D019540:Area Under Curve; D001794:Blood Pressure / Q000187:drug effects* / Q000235:genetics; D002319:Cardiovascular System / Q000187:drug effects; D020927:Dexmedetomidine / Q000008:administration & dosage*; D005260:Female; D005838:Genotype; D006239:Haplotypes; D006339:Heart Rate / Q000502:physiology; D006720:Homozygote; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D009638:Norepinephrine / Q000097:blood; D015990:Placebo Effect; D018341:Receptors, Adrenergic, alpha-2 / Q000737:chemistry / Q000235:genetics* / Q000378:metabolism; D016037:Single-Blind Method
chemical_list: C547768:ADRA2A protein, human; D058647:Adrenergic alpha-2 Receptor Agonists; D018341:Receptors, Adrenergic, alpha-2; D020927:Dexmedetomidine; D009638:Norepinephrine